{"pmid":32245835,"title":"The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges.","text":["The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges.","The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by SARS-CoV-2. In the pre-analytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time RT-PCR assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak.","J Clin Microbiol","Tang, Yi-Wei","Schmitz, Jonathan E","Persing, David H","Stratton, Charles W","32245835"],"abstract":["The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by SARS-CoV-2. In the pre-analytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time RT-PCR assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak."],"journal":"J Clin Microbiol","authors":["Tang, Yi-Wei","Schmitz, Jonathan E","Persing, David H","Stratton, Charles W"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245835","week":"202014|Mar 30 - Apr 05","doi":"10.1128/JCM.00512-20","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663169699633954817,"score":7.6048946,"similar":[{"pmid":32196430,"title":"Laboratory Diagnosis of Emerging Human Coronavirus Infections - The State of the Art.","text":["Laboratory Diagnosis of Emerging Human Coronavirus Infections - The State of the Art.","The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of 21st century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasal-pharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients.","Emerg Microbes Infect","Loeffelholz, Michael J","Tang, Yi-Wei","32196430"],"abstract":["The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of 21st century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasal-pharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients."],"journal":"Emerg Microbes Infect","authors":["Loeffelholz, Michael J","Tang, Yi-Wei"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196430","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1745095","keywords":["COVID-19","Human coronavirus","POCT","SARS-CoV-2","real-time PCR","serology"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1662334543156215808,"score":354.46494},{"pmid":32172228,"title":"Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","text":["Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19).","A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance.","Clin Chem Lab Med","Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario","32172228"],"abstract":["A novel zoonotic coronavirus outbreak is spreading all over the world. This pandemic disease has now been defined as novel coronavirus disease 2019 (COVID-19), and is sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the current gold standard for the etiological diagnosis of SARS-CoV-2 infection is (real time) reverse transcription polymerase chain reaction (rRT-PCR) on respiratory tract specimens, the diagnostic accuracy of this technique shall be considered a foremost prerequisite. Overall, potential RT-PCR vulnerabilities include general preanalytical issues such as identification problems, inadequate procedures for collection, handling, transport and storage of the swabs, collection of inappropriate or inadequate material (for quality or volume), presence of interfering substances, manual errors, as well as specific aspects such as sample contamination and testing patients receiving antiretroviral therapy. Some analytical problems may also contribute to jeopardize the diagnostic accuracy, including testing outside the diagnostic window, active viral recombination, use of inadequately validated assays, insufficient harmonization, instrument malfunctioning, along with other specific technical issues. Some practical indications can hence be identified for minimizing the risk of diagnostic errors, encompassing the improvement of diagnostic accuracy by combining clinical evidence with results of chest computed tomography (CT) and RT-PCR, interpretation of RT-PCR results according to epidemiologic, clinical and radiological factors, recollection and testing of upper (or lower) respiratory specimens in patients with negative RT-PCR test results and high suspicion or probability of infection, dissemination of clear instructions for specimen (especially swab) collection, management and storage, together with refinement of molecular target(s) and thorough compliance with analytical procedures, including quality assurance."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Simundic, Ana-Maria","Plebani, Mario"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32172228","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0285","keywords":["COVID-19","coronavirus","diagnosis","reverse transcription polymerase chain reaction (RT-PCR)"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1662334543649046528,"score":338.00662},{"pmid":32156329,"pmcid":"PMC7068162","title":"Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.","text":["Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.","Facing the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-volume respiratory testing is demanded in laboratories worldwide. We evaluated the performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed assay. We observed good analytical performance in clinical specimens. The fully automated workflow enables high-throughput testing with minimal hands-on time, while offering fast and reliable results.","Euro Surveill","Pfefferle, Susanne","Reucher, Svenja","Norz, Dominic","Lutgehetmann, Marc","32156329"],"abstract":["Facing the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-volume respiratory testing is demanded in laboratories worldwide. We evaluated the performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed assay. We observed good analytical performance in clinical specimens. The fully automated workflow enables high-throughput testing with minimal hands-on time, while offering fast and reliable results."],"journal":"Euro Surveill","authors":["Pfefferle, Susanne","Reucher, Svenja","Norz, Dominic","Lutgehetmann, Marc"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32156329","week":"202011|Mar 09 - Mar 15","doi":"10.2807/1560-7917.ES.2020.25.9.2000152","keywords":["*COVID-19","*SARS-CoV-2","*automation","*high-throughput PCR","*molecular diagnostic"],"link_comment_for":"31992387","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1662334543826255872,"score":284.6129},{"pmid":32104917,"title":"Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis.","text":["Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis.","The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (SARS-Cov-2) nucleic acid RT-PCR test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay which can detect IgM and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. This article is protected by copyright. All rights reserved.","J Med Virol","Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng","32104917"],"abstract":["The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (SARS-Cov-2) nucleic acid RT-PCR test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay which can detect IgM and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104917","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25727","keywords":["COVID-19","Lateral flow immunoassay","Point-of-Care Testing","SARS-CoV-2 Virus Infection","fingerstick blood","rapid IgM-IgG Combined test"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1662334544244637697,"score":275.976},{"pmid":32219885,"title":"Stability Issues of RT-PCR Testing of SARS-CoV-2 for Hospitalized Patients Clinically Diagnosed with COVID-19.","text":["Stability Issues of RT-PCR Testing of SARS-CoV-2 for Hospitalized Patients Clinically Diagnosed with COVID-19.","In this study, we collected a total of 610 hospitalized patients from Wuhan between Feb 2, 2020, and Feb 17, 2020. We reported a potentially high false negtive rate of RT-PCR testing for SARS-CoV-2 in the 610 hospitalized patients clinically diagnosed with COVID-19 during the 2019 outbreak. We also found that the RT-PCR results from several tests at different points were variable from the same patients during the course of diagnosis and treatment of these patients. Our results indicate that in addition to the emphasis on RT-PCR testing, clinical indicators such as CT images should also be used not only for diagnosis and treatment but also for isolation, recovery/discharge and transferring for hospitalized patients clinically diagnosed with COVID-19 during the current epidemic. These results suggested the urgent needs for standard of procedures(SOP) of sampling from different anatomic sites, sample transportation, optimization of RT-PCR, serology diagnosis/screening for SARS-CoV-2 infection, and distinct diagnosis from other respiratory diseases such as fluenza infections as well. This article is protected by copyright. All rights reserved.","J Med Virol","Li, Yafang","Yao, Lin","Li, Jiawei","Chen, Lei","Song, Yiyan","Cai, Zhifang","Yang, Chunhua","32219885"],"abstract":["In this study, we collected a total of 610 hospitalized patients from Wuhan between Feb 2, 2020, and Feb 17, 2020. We reported a potentially high false negtive rate of RT-PCR testing for SARS-CoV-2 in the 610 hospitalized patients clinically diagnosed with COVID-19 during the 2019 outbreak. We also found that the RT-PCR results from several tests at different points were variable from the same patients during the course of diagnosis and treatment of these patients. Our results indicate that in addition to the emphasis on RT-PCR testing, clinical indicators such as CT images should also be used not only for diagnosis and treatment but also for isolation, recovery/discharge and transferring for hospitalized patients clinically diagnosed with COVID-19 during the current epidemic. These results suggested the urgent needs for standard of procedures(SOP) of sampling from different anatomic sites, sample transportation, optimization of RT-PCR, serology diagnosis/screening for SARS-CoV-2 infection, and distinct diagnosis from other respiratory diseases such as fluenza infections as well. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Li, Yafang","Yao, Lin","Li, Jiawei","Chen, Lei","Song, Yiyan","Cai, Zhifang","Yang, Chunhua"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219885","week":"202013|Mar 23 - Mar 29","doi":"10.1002/jmv.25786","keywords":["COVID-19","RT-PCR"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1662540582067634176,"score":272.7951}]}